Table 3 Comparison of clinical, laboratory and radiological data of studied cases with and without GHD

Height SDS

−3.52 ± 0.3

−2.56 ± 0.1

6.11

0.043*

(−2.85- -4.21)

(−2.15- -2.91)

GV (cm/3 months)

1.21 ± 0.2

0.85 ± 0.1

5.99

0.041*

(0.7-2.23)

(0.1-1.83)

GV SDS

+1.56 ± 0.5

+0.91 ± 0.2

7.12

0.030*

(+0.72 - +2.11)

(-0.5 - +1.86)

Weight SDS

-1.68 ± 0.12

-1.58 ± 0.52

1.9

0.5

(-1.99 - +0.55)

(-2.01- +0.25)

BMI (kg/m2)

16.91 ± 0.25

17.31 ± 0.46

1.8

0.3

(15.56-18.12)

(14.53-17.92)

BMI SDS

-1.81 ± 0.10

-1.72 ± 0.32

2.1

0.5

(-1.9- -0.78)

(-2.10- -0.82)

Serum Zn (μg/dl)

45.71 ± 2.9

76.16 ± 5.9

18.12

<0.001***

(37.52-61.55)

(39.12 - 93.11)

Peak GH after insulin stimulation(ng/ml)

7.81 ± 0.1

11.61 ± 1.01

9.11

0.021*

(7.61-8.91)

(10.55-13.20)

Peak GH after clonidine stimulation (ng/ml)

7.14 ± 0.12

12.54 ± 1.21

10.16

0.01*

(6.92-8.53)

(10.88-14.11)

IGF-1 (ng/ml)

46.78 ± 6.5

100.12 ± 12.5

16.22

<0.001***

(36.52-59.11)

(72.55-115.69)

IGF-1 SDS

-2.72 ± 0.10

+0.38 ± 0.21

19.01

<0.001***

(-3.22- -2.11)

(-1.20- +0.55)

IGFBP-3 (ng/ml)

2006.22 ± 92

3445.11 ± 292

9.88

0.01*

(1195.45 - 2111.26)

(3124.45 - 3898.15)

-BA (years)

2.8 ± 1.0

5.7 ± 1.26

8.15

0.03*

(1.81-5.9)

(4.-9.25)

-BA SDS

-1.7 ± 0.12

-0.7 ± 0.14

11.22

0.01*

(-2.44 - +0.01)

(-1.14 - +0.22)